CBD FOR CHRONIC PAIN
A 2017 study explored whether CBD underlies the reward of pain relief. It provided evidence to suggest that CBD influences different dimensions of the response of rats to a surgical incision. This was one of the first studies to show that CBD can affect the perception of pain. (SOURCE).
A 2008 study reinforced the conception of CBD as the first clinically available endocannabinoid modulator. It also stated that CBD additional affects THC function by reducing associated intoxication, panic anxiety and tachycardia. It also discussed the discovery that CBD is able to promote signaling of the adenosine receptor A2A by inhibiting the adenosine transporter. The study wrapped up by explaining that CBD demonstrated that CBD was able to produce apoptosis in malignant cells and inhibit cancer-induced angiogenesis. (SOURCE).
Studies have suggested that they may result useful to treat diverse, diseases, including those related with acute or chronic pain. A 2008 review examined promising indications of cannabinoid receptor agonists to relieve pain. It found that studies have been made with CBD derivatives developed to inhibit peripheral pain responses and inflammation after binding to cannabinoid receptors. (SOURCE).
In adults with Chronic Pain, patients who were treated with cannabinoids are more likely to experience a clinically significant reduction in pain symptoms. (SOURCE).
CBD FOR ARTHRITIS
A 2019 review gave the overall effects of cannabinoids in inflammation and explained why they might be useful in the treatment of RA. It specifically found that CBD demonstrated anti-arthritic effects independent of cannabinoid receptors. In addition, the study showed that cannabinoids reduce pain by activating central and peripheral CB1, peripheral CB2 receptors and CBD-sensitive non-cannabinoid receptor targets. The study concluded by recommending CBD to induce cannabinoid receptor-independent anti-inflammatory effects. (SOURCE).
Osteoarthritis (OA) is a multifactorial joint disease, which includes join degeneration, intermittent inflammation, and peripheral neuropathy. A 2017 study was to determine whether CBD is anti-nociceptive in OA, and whether inhibition of inflammation by CBD could prevent the development of OA pain and joint neuropathy. The study showed acute transient joint inflammation was reduced by local CBD treatment. The study concluded that local administration of CBD blocked OA pain. It found prophylactic CBD treatment prevented the later development of pain and nerve damage in these OA joints. These findings suggest that CBD may be a safe, useful therapeutic for treating OA joint neuropathic pain. (SOURCE).
Current arthritis treatments often have side-effects attributable to active compounds and route of administration. CBD has been shown to reduce inflammation and pain without side-effects. A 2016 study examined the efficacy of topical CBD to reduce inflammation and pain in a rat knee joint model. The results showed that topical CBD significantly reduced joint swelling, limb posture scores as a rating of spontaneous pain, immune cell infiltration and thickening of the synovial membrane. The data found in this study indicated that topical CBD has therapeutic potential for relief of arthritis pain-related behaviors and inflammation without evident side-effects. (SOURCE).
CBD FOR INFLAMMATORY & NEUROPATHIC PAIN
A 2007 study investigated its therapeutic potential on neuropathic and inflammatory pain in animal models. The results indicated a potential therapeutic use of CBD in chronic painful states. (SOURCE).
Paclitaxel (PAC) is associated with chemotherapy-induced neuropathic pain (CIPN) that can lead to cancer patients abandoning treatment. Researchers previously reported that chronic administration of CBD prevents PAC-induced mechanical and thermal sensitivity in mice. In 2014, the same researchers evaluated whether CBD negatively effects nervous system function or chemotherapy efficacy. They concluded that CBD is protective against PAC-induced neurotoxicity mediated in part by the 5-HT (1A) receptor system. In addition, CBD produced no conditioned rewarding effects and did not affect conditioned learning and memory. (SOURCE).
A 2012 study showed that systemic and intrathecal administration of CBD significantly suppresses chronic inflammatory and neuropathic pain without causing apparent analgesic tolerance in rodents. The study suggests that cannabinoids may represent a novel class of therapy for chronic pain. (SOURCE).
CBD PANCREATIC INFLAMMATION
A 2016 study investigated the impact of CBD treatment on early pancreatic inflammation in NOD mice. The results showed that CBD-treated NOD mice developed type 1 diabetes later and showed significantly reduced leukocyte activation and increased FCD in the pancreatic microcirculation. It concluded that CBD treatment reduced markers of inflammation in the microcirculation of the pancreas. (SOURCE)
CBD LIVER INJURY
A 2017 study investigated the effects of CBD on liver injury induced by alcohol. The study concluded that CBD may have therapeutic potential in the treatment of alcoholic liver disease associated with inflammation, oxidative stress and steatosis. (SOURCE). More human trials are needed, but the animal models are very promising.
CBD FOR IRRITABLE BOWEL SYNDROME
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder commonly associated with abdominal cramping and changes in bowel movement patterns. Approximately 11% of the world’s population suffers from some type of IBS. In animal models, endocannabinoids acting on CB1 receptors inhibit gastric and small intestinal transit and colonic propulsion. Cannabinoids have the potential to help relieve symptoms of IBS. (SOURCE).